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1 GENERAL PART 
1.1 INTRODUCTION 
Intoxications and poisonings of drugs had occurred within living memory. Owing to 
the desire of detecting of and protecting from such poisons a natural scientific 
working field developed along side, analytical toxicology [1]. The major fields of 
analytical toxicology are screening, identification, confirmation, and quantification of 
foreign compounds such as drugs and/or poisons [2]. The gained analytical results 
are fundamental for the consecutive pharmacological and toxicological interpretation, 
needed for the advisory service in clinical toxicology. This helps to achieve an 
optimized drug treatment in such intoxications or poisonings cases. 
Drug classes often reported to cause possible abuse, intoxication, and poisoning 
cases are psychotic drugs (antidepressants (AD) and neuroleptics (NL)), 
benzodiazepines (BZ) and Z-drugs, hypnotics, antiepileptics, analgesics, 
antihistamines, and cardiac drugs. ADs, NLs, and BZs are of special interest because 
of either their narrow therapeutic range or there high potential causing tolerance and 
dependence. Furthermore, therapeutic drug monitoring [3], compliance testing, and 
drug absence screening are also performed in clinical toxicology. Additionally, a 
possible Munchausen (by proxy) syndrome should be confirmed or denied. 
To screen for different poisons and to evaluate the level of intoxication, body fluids of 
these intoxicated patients are often sent to a toxicology lab. Due to the strong relation 
between blood plasma concentrations and clinical symptoms, in most of the cases, 
blood is usually used for identification and quantification. As blood contains disturbing 
matrices, such as proteins and lipids, an appropriate sample preparation is needed 
prior to instrumental analysis [2, 4, 5]. Depending on the analytes to extract, solid-
phase extraction [6-10], liquid-liquid extraction [6, 11-19] or online extraction [20] are 
normally used.  
For screening, identification, and quantification, specific and sensitive analytical 
procedures covering many analytes of interest are needed, as the kind, number, and 
amount of poison(s) are not known in advance. Combining high separation power 
(gas chromatography) with high identification power (mass spectrometry) made such 
an intention possible and easier in handling [1, 21]. As a resultant of the new 
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developments in the liquid chromatography (LC)- mass spectrometry (MS) sector, 
many of so called multi-analyte screening procedures were published recently [2, 22-
25]. The intention of such multi-analyte procedures is to monitor many analytes of 
interest with a single sample preparation and analyzing method. This makes it 
preferable, because they make the analytical process much simpler, faster, and more 
cost effective. Altogether, this is of importance because often only a limited amount of 
sample is available and the number of different analytes is unknown in the beginning 
of the analysis. 
There are several strategies for selecting analytes to be included in particular multi-
analyte procedures; according to chemical drug classes, in relation to 
pharmacological effects and/or the need for a quick and easy screening or 
quantification procedure. Several multi-analyte methods containing analytes from the 
same drug classes have been published for plasma and/or serum so far. For the 
detection of ADs, various GC-MS or LC-MS procedures have been described [8-10, 
17, 18, 20, 26, 27]. Others have published methods for the detection of NLs [7, 19, 
28], BZs [11-14, 14, 15, 29, 30], antiepileptics [31], oral antidiabetics [16], beta-
blockers [32], and antihistamines [33]. Some working groups published multi-analyte 
methods arranged from compounds of different drug classes in relation to their 
pharmacological effects [13, 30, 34-36] and/or the need for a quick and easy 
screening or quantification procedure [6, 37, 38].  
In clinical and forensic toxiclogy, there is also a strong need for precise and accurate 
quantification of these analytes. As the results of toxicological analysis can have 
serious clinical and/or legal consequences, the quality must be strictly controlled in 
method validation and quality control samples [2, 39-41]. Peters et al. [42, 43] 
described extensively which parameters should be included in validation experiments 
for quantitative methods; selectivity, calibration model (linearity), recovery, matrix 
effects, stability, accuracy (bias), precision (repeatability, intermediate precision) and 
the lower limit of quantification (LLOQ). Especially using LC-MS techniques, testing 
for matrix effects and other possible ion suppression or enhancement effects is 
necessary. The commonly used ionization (APCI and ESI) techniques in LC-MS are 
susceptible for such effects, which can cause serious problems during identification 
as well as quantification. Additional parameters which may be relevant include LOD, 
reproducibility, and ruggedness (robustness).  
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1.2 PHARMACOLOGY AND TOXICOLOGY 
An overview of the pharmacology and toxicology of the most important drug classes 
are given in the following. 
 
1.2.1 Antidepressants  
 
ADs are widely used as a psychiatric medication for treatment of mood and anxiety 
disorders. As depression is associated with under representation and disbalances of 
the neurotransmitters serotonin, dopamine, and norepinephrine in the brain, all ADs 
are acting as enhancers of these neurotransmitters [44, 45]. These can be achieved 
by either inhibiting the re-uptake of the neurotransmitters or by inhibiting the 
degradation pathway/enzyme. According to their mode of action, ADs can be 
distinguished into: tri- and tetracyclic ADs, selective serotonin and/or norepinephrine 
re-uptake inhibitors and monoamine oxidase A inhibitors [46]. In Fig. 1, typical 
examples of the mentioned groups are shown, also representing the difference in 
chemical structures. 
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Fig. 1  Chemical structures of the different ADs 
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The tri- and tetracyclic ADs are not only acting as serotonin and norepinephrine re-
uptake inhibitors, but also have effects on histamine H1, muscarine, α-adrenaline and 
5-HT2 receptors. These can lead to unpleasant side-effects such as sedation, dry 
mouth, tachycardia, constipation, which often increases non-compliance in 
psychiatric patients. The newer generations of ADs are more specific reuptake 
inhibitors leading to more serotonin- and/or norepinephrine-related adverse effects 
such as extrapyramidal symptoms, sleeping disorders, tachycardia, and tremor. ADs 
alone, particularly the classic ones, and in combination with other drugs may cause 
severe poisoning after overdose. 
 
1.2.2 Neuroleptics 
 
Antipsychotic drugs also known as NLs are in use as a psychiatric medication to treat 
several mental disorders such as psychosis, schizophrenia, hallucinations, mania, 
sleeping disorders, and dementia of mood and anxiety disorders. Although the 
development of schizophrenia is not yet fully understood the neurochemical 
hypotheses of an overactivation of the dopaminergic system is well accepted. 
Nevertheless, the serotonergic system seems to be part of the pathogenesis of 
schizophrenia, as well. Therefore, NLs are all acting as dopamine (D) receptor 
antagonists, with prevalences to different subtypes, but also have effects on 
histamine H1, muscarine, α-adrenaline, and 5-HT2 receptors [44-46]. The classical 
NLs have prevalence on D2-and D1-receptors, causing extrapyramidal side-effects. 
They can also lead to side-effects such as sedation, hypotention, reflectoric 
tachycardia, dry mouth, obstipation, and accommodation caused by blocking the 
histamine H1, muscarine and/or α-adrenaline receptors. The atypical neuroleptics act 
as D2- or D4- as well as 5-HT2 receptor antagonists, causing no or slight 
extrapyramidal side-effects. The typical NLs are represented by phenothiazines, 
thioxanthenes, and butyrophenones. Atypical NLs, such as clozapine, olanzapine, 
zotepine, amisulpride, sulpiride, risperidone, ziprasidone, and aripiprazole cannot be 
sorted according to any specific structure [46]. Typical examples of both groups are 
depicted in Fig. 2.  
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Fig. 2  Chemical structures of the different NLs 
 
However, all the NLs may cause unpleasant side effects and severe poisoning after 
overdose. 
 
1.2.3 Benzodiazepines 
 
For the treatment of sleeplessness, anxiety, increased muscle tone, or epilepsy, BZs 
as well as the pharmacologically related Z-drugs, zaleplone, zolpidem, and zopiclone, 
are often assembled. The balance between activating and inhibiting neurotransmitter 
transmission is disturbed and has often moved to more activating synaptic response 
in the above mentioned diseases. To increase the inhibitory synaptic response the 
activity of the classical inhibiting neurotransmitter γ-aminobutyric acid (GABA) has to 
be increased. BZs and related Z-drugs act very selectively on GABAA receptors, 
amplifying the GABA affinity to its receptor site [44-46]. The frequency of the chloride 
channel opening is increased, resulting in an inhibitory synaptic response. The side-
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effects of these agonists are similar; mainly dizziness, prolonged sleep, reduced 
ability to concentrate, leading e.g. to driving impairment [47]. Nevertheless, BZs can 
cause severe, even life-threatening, respiratory depression if taken in combination 
with other CNS-depressing substances, particularly alcohol. Furthermore, they have 
a high potential to produce tolerance and dependence. Examples of BZs and Z-drugs 
are given in Fig. 3. 
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Fig. 3  Chemical structures of the different BZs and Z-drugs 
 
1.2.4 Beta-Blockers 
 
ß-Adrenoceptor antagonists, briefly beta-blockers, are used for treatment of 
hypertension, angina pectoris, cardiac insufficiency, and cardiac dysrhythmias. As all 
these diseases go along with a higher activation of the sympathico tonus, they act as 
antagonists of the ß-Adrenoceptors [44, 45]. Bradycardia, hypotension, 
bronchoconstriction, hypoglycemia, and fatigue are serious side-effects. In Fig 4, the 
typical structure of beta-blockers is depicted. Although there is no strong correlation 
between the plasma concentration of beta-blockers and their pharmacological and 
toxic effects [48], overdose of beta-blockers may lead to life-threatening situations  
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[49-51]. As they reduce heart rate and tremor, the World Anti Doping Agency 
prohibits the use of these drugs In-Competition in several sports e.g. archery, 
bobsleigh. dart, motorcycling, and shooting  [52]. Therefore, analytical methods for 
screening, identification, and quantification are needed. 
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Fig. 4  Typical structure of the beta-blockers 
 
1.2.5 Oral Antidiabetics 
 
Oral antidiabetics of the sulfonylurea-type are in use for treating diabetes mellitus 
type II. By blocking the adenosine triphosphate dependent potassium channel, they 
act as insulin sensitizer [44, 45]. Due to this mode of action, these drugs can lead to 
severe side effects such as hypoglycemia. As these drugs are not only used 
regularly, but are also abused in cases of Munchausen (by proxy) syndrome this can 
lead to serious poisonings. 
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1.2.6 Analytes measured in the context of brain death diagnosis 
 
In this context, various analytes of different drug classes, BZs, anesthetics, narcotics, 
and opioids have to be monitored (see Fig. 6) to assure the certain absence of these 
drugs prior to organ explantation [53, 54]. As these drugs can suppress the cerebral 
activity, falsifying an electroencephalogram, this must be an important prerequisite in 
the determination of brain death diagnosis [54]. The studied BZs, diazepam, 
oxazepam, midazolam, and nordazepam, are agonists of the GABAA receptors and 
are widely used because of their anxiolytic, sedative, muscle relaxing, and 
anticonvulsive effects. Etomidate and ketamine, both used as anesthetics with a 
short half-life, act as GABAA receptor agonist or NDMA-receptor blocker, 
respectively. Whereas etomidate possesses no analgesic effect, ketamine possesses 
a strong analgesic action. The synthetic opioids, alfentanil, fentanyl, piritramide and 
sufentanil, as well as the opiate morphine are used intravenously to treat severe pain 
or as an adjunct to anesthesia. They are strong agonists on the µ-receptors and have 
an agonistic effect on the δ-receptors as well [44, 45].  
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Fig. 6  Typical analytes of measured in the context of brain death diagnosis 
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2 AIMS AND SCOPES 
 
Multi-analyte LC-MS methods have already been described, but only for a limited 
number of drugs [13, 30, 36, 38]. Therefore, a new multi-analyte procedure should be 
developed covering all relevant drugs of important drug classes.  
As triple quadrupole LC-MS/MS devices combine high sensitivity with good 
identification and quantification power, this technology should be used for secure 
identification and reliable quantification of drugs in plasma. Today, ultra high 
performance liquid chromatography (UHPLC) is the gold standard in separation 
technology, as the number of theoretical plates is high and therefore high separation 
power is given to get sufficient separation results and to seprate matrix. 
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Therefore, the aims of this presented study were: 
 
 
   To develop a multi-analyte UHPLC-MS/MS method covering the most 
common drug classes involved in abuse and intoxication cases. 
 
       Antidepressants (35 analytes) 
    Neuroleptics (31 analytes) 
    Benzodiazepines and Z-drugs (28 analytes) 
    Beta-blockers (25 analytes)  
    Oral antidiabetics (10 analytes) 
    Analytes measured in the context of brain death diagnosis 
    (11 analytes) 
 
 To develop this multi-analyte UHPLC-MS/MS method considering the following 
facts. 
 
   One chromatographic system should be used for separation. 
 
   One sample preparation should be found for extracting all analytes. 
 
 Testing for possible ion suppression/enhancement on the deuterated 
internal standards caused by the non labeled analytes. 
 
 Testing for possible ion suppression/enhancement on co-eluting 
analytes in the same drug class and between other drug classes. 
 
 
  To validate this multi-analyte method according to national and international 
  accepted guidelines for the most important and biggest drug classes. 
 
       Antidepressants (35 analytes) 
    Neuroleptics (31 analytes) 
    Benzodiazepines and Z-drugs (28 analytes)
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3 PUBLICATIONS OF THE RESULTS 
The results of the studies were published in the following papers: 
 
3.1 FAST AND SIMPLE PROCEDURE FOR LIQUID-LIQUID EXTRACTION OF 136 
ANALYTES FROM DIFFERENT DRUG CLASSES FOR DEVELOPMENT OF A 
LIQUID CHROMATOGRAPHIC-TANDEM MASS SPECTROMETRIC 
QUANTIFICATION METHOD IN HUMAN BLOOD PLASMA [55] 
 (DOI 10.1007/S00216-010-3820-7) 
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3.2 SYSTEMATIC INVESTIGATION OF ION SUPPRESSION AND ENHANCEMENT 
EFFECTS OF FOURTEEN STABLE-ISOTOPE-LABELED INTERNAL STANDARDS 
BY THEIR NATIVE ANALOGUES USING ATMOSPHERIC-PRESSURE CHEMICAL 
IONIZATION AND ELECTROSPRAY IONIZATION AND THE RELEVANCE FOR 
MULTI-ANALYTE LIQUID CHROMATOGRAPHIC/MASS SPECTROMETRIC  
PROCEDURES [56]  
 (DOI: 10.1002/RCM.4459) 
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3.3 ION SUPPRESSION AND ENHANCEMENT EFFECTS OF CO-ELUTING ANALYTES 
IN MULTI-ANALYTE APPROACHES: SYSTEMATIC INVESTIGATION USING 
ULTRA-HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY/MASS 
SPECTROMETRY WITH ATMOSPHERIC-PRESSURE CHEMICAL IONIZATION OR 
ELECTROSPRAY IONIZATION [57] 
 (DOI: 10.1002/RCM.4736) 
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3.4 FULL VALIDATION AND APPLICATION OF AN ULTRA HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHIC-TANDEM MASS SPECTROMETRIC PROCEDURE 
FOR TARGET SCREENING AND QUANTIFICATION OF 34 ANTIDEPRESSANTS 
IN HUMAN BLOOD PLASMA AS PART OF A COMPREHENSIVE MULTI-ANALYTE 
APPROACH [58] 
 (DOI 10.1007/S00216-011-4959-6) 
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3.5 ULTRA HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC-TANDEM MASS 
SPECTROMETRIC MULTI-ANALYTE PROCEDURE FOR TARGET SCREENING 
AND QUANTIFICATION IN HUMAN BLOOD PLASMA: VALIDATION AND 
APPLICATION FOR 31 NEUROLEPTICS, 28 BENZODIAZEPINES AND Z-DRUGS 
[59] 
 (DOI 10.1007/S00216-011-5187-9) 
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4 CONCLUSIONS 
 
Systematic data of all steps in the development of a multi-analyte approach for fast 
target screening and quantification in plasma were shown in the respective papers 
[55-59]. Analytes of six of the most important drug classes in clinical toxicology were 
implemented into this procedure resulting in 136 analytes. After testing different 
column types and different mobile phase compositions, an UHPLC system was found 
to be sufficient for the separation of most of the analytes. For separating the analytes 
with different chemical structures, only one column and one gradient was used. In 
addition, the triple quadrupole technology in the time-schedule monitoring mode was 
shown to be sensitive enough in most of the cases. Furthermore, a fast and simple 
extraction procedure covering a wide range of different drug classes was developed. 
Recovery, matrix effects, and process efficiency tests were performed. The extraction 
procedure showed good results for 119 analytes and were comparable to extraction 
results of other multi-analyte methods. The recovery results, calculated without 
compensation by internal standardization were compared to those using internal 
standards. It could be shown that recovery results are more or less the same, but the 
reproducibility is better, as the internal standards compensate different variations of 
plasma. 
Nevertheless, as there were still some co-eluting analytes, stable isotope labeled 
(SIL) internal standards (IS) and non labeled analytes and co-eluting analytes from 
the same and other drug classes, ion suppression and enhancement tests were 
performed. The ion suppression/enhancement tests on the SIL-IS caused by the non 
labeled analytes and of other co-eluting analytes showed severe effects especially 
using electrospray ionization technique. Therefore, the SIL-IS should be selected 
very carefully, especially if used for the quantification of analytes others than the non-
labeled one. The presented studies showed the analytical fundamentals of such ion 
suppression and enhancement tests especially during method development and 
validation of multi-analyte procedures using LC-MS/MS technology. It was shown that 
these effects can influence the quantification results and lead to clinical or forensic 
misinterpretation. The cause of this ion suppression or enhancement could 
unfortunately not be found, but it can be concluded that a combination of different 
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effects, such as structure, molecular weight, concentration, and the chromatographic 
behavior of the analytes and the co-eluting analyte, should be responsible. 
The UHPLC-MS/MS approach was finally validated for the drug classes of ADs, NLs, 
and, BZs with respect to selectivity, cross talk, calibration model, accuracy, precision, 
processed sample stability, freeze/thaw stability, bench top stability, lower limit of 
quantification (LLOQ), limit of detection, and applicability. Furthermore, accuracy and 
precision were obtained with full and one-point calibration. This approach allowed 
selective target screening as well as accurate and precise quantification of 28 ADs, 
24 NLs, and 21 BZs. 
The method fulfilled the requirements for a validated assay and has proved to be 
efficient in authentic cases and external quality control samples. Thus, it allows drug 
monitoring and confirmation of diagnosis of an overdose situation caused by 
ingestion of ADs, NLs, and BZs. Furthermore, the time- and cost-saving one-point 
calibration was shown to be applicable for many analytes for daily routine and 
especially for emergency cases. Nevertheless, analytes not fulfilling the validation 
criteria and/or having higher LLOQs than the lower therapeutic concentrations, 
seemed to have in common rather low therapeutic plasma concentrations and late 
retention times in the used chromatographic system. The low analyte concentrations 
and the higher amount of acetonitrile at the end of the chromatographic system result 
in narrow peaks. Because of the use of this method as multi-analyte approach, the 
amount of monitored transitions is high (>350) and it is not possible to get more than 
10 data points of these peaks in the used settings. Although the number of data 
points is enough, the peaks could sometimes not be described as Gaussian curves 
because of fronting and tailing. Due to the high number of SRM transitions, narrow 
peaks could lead to a missing data point resulting in variations of the peak areas. 
E.g. using a more sophisticated sample processing, reducing the amount of 
transitions and/or changing the chromatographic system could solve this problem. As 
this method was set up for a multi-analyte approach changing these parameters will 
affect other analytes and is not reasonable in this particular case. It shows the 
limitations of broad multi-analyte procedures particularly using UHPLC after simple 
workup. This should always be in mind when using this method.  
Regarding the fact that a lot of analytes with different chemical structures are 
implemented in this fast and simple work-up, compromises concerning recovery, 
precision, and LLOQ had to be made in some cases. 
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5 SUMMARY 
 
In the presented studies, the development of an UHPLC-MS/MS approach for fast 
target screening and quantification in plasma was described. This approach covered 
136 analytes out of the drug classes of antidepressants, neuroleptics, 
benzodiazepines, beta-blockers, oral antidiabetics, and analytes to be determined in 
the context of brain death diagnosis. Further, it was possible to find one 
chromatographic system with the same column and mobile phase compositions to 
separate almost all these analytes sufficiently. A fast and simple liquid-liquid 
extraction for all these analytes was developed. In addition, the presented studies 
showed that ion suppression and enhancement tests were essential, particularly for 
the selection of internal standards for UHPLC-MS/MS multi-analyte procedures and 
for combining co-eluting analytes during method validation. Furthermore, this 
approach was fully validated for the most important drug classes of antidepressants, 
neuroleptics, and benzodiazepines. This approach was valid for 28 antidepressants, 
24 neuroleptics, and 21 benzodiazepines. In addition, the applicability was shown 
successfully using authentic human blood samples and external quality control 
samples. The cost and time saving one-point calibration was shown to be sufficient 
for more than half of the analytes. 
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7 ZUSAMMENFASSUNG 
 
Im Rahmen dieser Dissertation wurde die Entwicklung einer UHPLC-MS//MS 
Methode für schnelles Target-Screening und Quantifizierung im Plasma beschrieben. 
Die Methode umfasste 136 Arzneistoffe aus den Stoffgruppen der Antidepressiva, 
Neuroleptika, Benzodiazepine, Betablocker, orale Antidiabetika und Arzneistoffe, die 
im Rahmen der Hirntoddiagnostik untersucht werden müssen. Weiterhin war es 
möglich, ein chromatographisches System, unter Verwendung derselben Säule und 
Fließmittelzusammensetzung, für die Trennung aller Arzneistoffe zu finden. Eine 
schnelle und einfache Flüssig-Flüssig-Extraktion wurde für alle Arzneistoffe 
entwickelt. Die Notwendigkeit von Untersuchungen zur Ionenunterdrückung und 
Ionenerhöhung konnte ebenfalls in dieser Arbeit belegt werden. Diese 
Untersuchungen waren für die Wahl des internen Standards für LC-MS/MS 
Methoden und für die Zusammensetzung von co-chromatographierenden Stoffen 
wichtig. Weiterhin wurde diese Methode für die wichtigsten Stoffgruppen nämlich die 
Antidepressiva, Neuroleptika und Benzodiazepine voll validiert. Es konnte gezeigt 
werden, dass die Methode für 28 Antidepressiva, 24 Neuroleptika und 21 
Benzodiazepine valide war. Die Anwendbarkeit wurde mittels humaner authentischer 
Plasmaproben und mittels externen Qualitätskontrollproben gezeigt. Die kosten- und 
zeitsparende Ein-Punkt-Kalibrierung erwies sich für über die Hälfte der Arzneistoffe 
als akzeptabel. 
